麦卡姆坦对一名表现为梗阻性肥厚型心肌病表型的心脏移植患者的安全性和有效性。
Mavacamten Safety and Efficacy in a Heart Transplant Patient Exhibiting Obstructive Hypertrophic Cardiomyopathy Phenotype.
作者信息
Abood Zaid, Ghafoor Asad, Ashraf Muddasir, Peters Matthew, Galazka Patrycja, Misicka Amanda, Jan M Fuad, Jahangir Arshad, Tajik A Jamil
机构信息
Aurora Cardiovascular and Thoracic Services, Aurora Sinai/Aurora St. Luke's Medical Centers, Aurora Health Care, Milwaukee, Wisconsin, USA.
Division of Cardiovascular Medicine, University of Wisconsin School of Medicine and Public Health, Milwaukee Clinical Campus, Milwaukee, Wisconsin, USA.
出版信息
JACC Case Rep. 2024 Aug 21;29(16):102454. doi: 10.1016/j.jaccas.2024.102454.
Hypertrophic cardiomyopathy is the most common inherited cardiac disease, exhibiting diverse phenotypes. Obstructive hypertrophic cardiomyopathy occurs in about two-thirds of cases and carries a worse prognosis. Mavacamten use in heart transplant recipients is limited. This paper reports a recipient who developed severe symptomatic obstructive hypertrophic cardiomyopathy phenotype/phenocopy and was initiated on mavacamten.
肥厚型心肌病是最常见的遗传性心脏病，表现出多种表型。梗阻性肥厚型心肌病约占病例的三分之二，预后较差。马伐卡坦在心脏移植受者中的应用有限。本文报告了一名出现严重症状性梗阻性肥厚型心肌病表型/拟表型并开始使用马伐卡坦的受者。
Zotero 插件